/ 05 / RESEARCH CONTEXT
GHK-Cu dosage in the research record: concentrations, routes, and stability.
What concentrations and routes the studies actually used, what is known about clearance, and why no human pharmacokinetic half-life has been validated. Research context, not a protocol.
Concentrations used in GHK-Cu research
GHK-Cu dosage in the literature spans a wide range because the routes and models differ. This section describes what was administered to which model — it is not a human dosing guide, and there is no validated human protocol for systemic GHK-Cu.
In vitro, fibroblast collagen synthesis responds across 10⁻¹² to 10⁻⁹ M, with onset between 10⁻¹² and 10⁻¹¹ M and a peak near 10⁻⁹ M [1]. Topical cosmetic and clinical formulations run roughly 0.05% to 2% (w/w) in creams, serums, and gels [3]. Rodent systemic studies used markedly higher loads by intraperitoneal route — mouse silicosis at 2 and 20 mg/kg, and a DSS-colitis model at 20 mg/kg by oral gavage [7]. Aging and cognition studies in mice used intranasal GHK at 15 mg/kg [7]. The human hair-loss trial applied the ALAVAX 5-ALA + GHK complex topically at 50-100 mg/mL [4]. The orders-of-magnitude gap between the picomolar cell-culture window and the milligram-per-kilogram rodent doses is itself a reason caution is warranted in reading across models.
Routes studied and the half-life question
GHK-Cu has been studied across many routes: topical (cream, serum, liposome, nano-lipid carrier, wound dressing), intraperitoneal, intranasal, oral gavage, intravenous, and intradermal microneedle delivery [3][14]. Topical is the route with human data and a long cosmetic safety history; the systemic routes are rodent-only.
No rigorous human pharmacokinetic half-life has been published. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases — a rat HPLC study documented rapid metabolism of GHK to the dipeptide histidyl-lysine after intravenous dosing [10]. Secondary literature cites a short systemic elimination half-life on the order of 1-2 hours, with the copper-chelated complex more stable than free GHK. Topical application instead forms a dermal copper depot, with about 97 µg/cm² retained over 48 hours, giving prolonged local availability [5]. The practical takeaway from the record is that GHK-Cu behaves very differently by route — fast systemic clearance versus a slow-release skin depot.
Stability and handling in the literature
Stability is a defining property of the complex. GHK-Cu has a very high copper stability constant (log K ~16.4), far higher than free GHK, which limits pro-oxidant free-copper release [6]. It is most stable near pH 5-6.5 at a 1:1 copper-to-peptide ratio. The blue-violet color of a reconstituted solution is the expected Cu(II) d-orbital absorption and indicates an intact complex, whereas a shift to brown or green signals oxidation or precipitation [3].
Two handling facts dominate the formulation literature. First, strong reducing agents — ascorbic acid below about pH 3.5 — reduce Cu(II) and break the complex, and low-pH acids can compete for copper [3]. Second, free GHK's hydrophilicity (clogP -2.24) limits passive skin penetration, which is why palmitoylation, liposomal encapsulation, and microneedle pretreatment are the active areas of delivery research [14].